Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma

Retrospective Analysis of Diffuse Large B-cell Lymphoma: Identification of Factors Associated With Treatment Resistance Via Gene Expression Profile

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01606605

Enrollment

350

Registered

2012-05-25

Start date

2011-01-31

Completion date

2012-12-31

Last updated

2013-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Large B-cell Lymphoma

Keywords

Lymphoma, Prognosis, Relapse, Gene, microRNA

Brief summary

The investigators perform a retrospective microarray gene expression profiling study of FFPE from a cohort of DLBCL patients with whole genome cDNA mediated Annealing Selection and Ligation (WG-DASL) assay. The investigators also study the pattern of microRNA from patients with diffuse large B-cell lymphoma. The results of gene expression profiles and microRNA is correlated with clinical outcomes of diffuse large B-cell lymphoma.

Detailed description

1. Whole genome cDNA mediated Annealing Selection and Ligation (WG-DASL) assay * Diffuse large B-cell lymphoma patients * Paraffin-embedded tissue * End points: Progression-free survival, overall survival * Statistics: Leave one-out method 2. Nano string assay for microRNA * Diffuse large B-cell lymphoma patients * Paraffin-embedded tissue * End points: Progression-free survival, overall survival * Statistics: Leave one-out method

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Patients diagnosed with diffuse large B-cell lymphoma * Patients with tissue blocks available for study * Patients with adequate medical records

Exclusion criteria

* Patients diagnosed with other subtypes of lymphoma

Design outcomes

Primary

Measure	Time frame
Number of patients who relapse or progress after 1st line chemotherapy	two years

Secondary

Measure	Time frame
Number and type of genes and microRNA which are significantly related with relapse or progression (P < 0.05)	two years

Countries

South Korea

Outcome results